- Home
- NWL vs NAMS Comparison
NWL vs NAMS Comparison
Compare NWL & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWL
- NAMS
- Stock Information
- Founded
- NWL 1903
- NAMS 2019
- Country
- NWL United States
- NAMS Netherlands
- Employees
- NWL N/A
- NAMS N/A
- Industry
- NWL Plastic Products
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- NWL Industrials
- NAMS Health Care
- Exchange
- NWL Nasdaq
- NAMS Nasdaq
- Market Cap
- NWL 2.4B
- NAMS 2.7B
- IPO Year
- NWL N/A
- NAMS N/A
- Fundamental
- Price
- NWL $5.90
- NAMS $23.92
- Analyst Decision
- NWL Buy
- NAMS Strong Buy
- Analyst Count
- NWL 8
- NAMS 10
- Target Price
- NWL $7.31
- NAMS $41.40
- AVG Volume (30 Days)
- NWL 7.5M
- NAMS 1.0M
- Earning Date
- NWL 10-24-2025
- NAMS 11-05-2025
- Dividend Yield
- NWL 4.73%
- NAMS N/A
- EPS Growth
- NWL N/A
- NAMS N/A
- EPS
- NWL N/A
- NAMS N/A
- Revenue
- NWL $7,397,000,000.00
- NAMS $64,006,000.00
- Revenue This Year
- NWL N/A
- NAMS N/A
- Revenue Next Year
- NWL $1.33
- NAMS N/A
- P/E Ratio
- NWL N/A
- NAMS N/A
- Revenue Growth
- NWL N/A
- NAMS 762.15
- 52 Week Low
- NWL $4.22
- NAMS $14.06
- 52 Week High
- NWL $11.78
- NAMS $27.35
- Technical
- Relative Strength Index (RSI)
- NWL 50.66
- NAMS 46.13
- Support Level
- NWL $5.85
- NAMS $24.18
- Resistance Level
- NWL $6.26
- NAMS $27.35
- Average True Range (ATR)
- NWL 0.23
- NAMS 1.37
- MACD
- NWL -0.02
- NAMS -0.19
- Stochastic Oscillator
- NWL 19.89
- NAMS 6.03
About NWL Newell Brands Inc.
Newell Brands Inc is an American consumer goods company with a strong portfolio of well-known brands, including Rubbermaid, Sharpie, Graco, Coleman, Rubbermaid Commercial Products, Yankee Candle, Paper Mate, FoodSaver, Dymo, EXPO, Elmer's, Oster, NUK, Spontex and Campingaz. The group is focused on delighting consumers by lighting up everyday moments. Its segments are Home and Commercial Solutions, Learning and Development, and Outdoor and Recreation. The group geographic areas are the United States, Canada, Europe, the Middle East and Africa, Asia Pacific, and Latin America.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.